MSD Licenses Evaxion's EVX-B3, Cancer Vaccine EVX-01 Shows Strong Phase 2 Data, Cash Runway to H2 2027
EVAX has more than doubled off its 52-week low of $1.2.
Summary
Evaxion announced a comprehensive business update and full-year 2025 financial results, highlighting a transformational year. Key achievements include the historic licensing of its infectious disease vaccine candidate EVX-B3 by MSD, impressive two-year Phase 2 data for its personalized cancer vaccine EVX-01, and the addition of two new candidates (EVX-04 and EVX-B4) to its R&D pipeline. The company also significantly strengthened its financial position through partnerships and capital market activities totaling over $30 million, extending its cash runway into the second half of 2027. This announcement follows a 20-F filing earlier today which indicated significant financial improvement for 2025, with this news release providing the crucial operational and pipeline details that underpin that financial strength. For a micro-cap biotech, the MSD licensing deal represents a major validation and potential revenue stream, while the positive Phase 2 data for EVX-01 is a significant de-risking event for its lead oncology asset. The extended cash runway into H2 2027 substantially alleviates near-term financing concerns. Investors will now watch for further EVX-01 data, the planned Phase 1 trial for EVX-04, and continued partnership developments as the company expands its AI-Immunology platform.
At the time of this announcement, EVAX was trading at $3.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.6M. The 52-week trading range was $1.20 to $12.15. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.